Karyopharm Therapeutics reported $980K in Cost of Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
TG Therapeutics TGTX:US USD 2K 21K
Abbott ABT:US USD 4.59B 36M
Abbvie ABBV:US USD 4.23B 86M
Amgen AMGN:US USD 1.75B 159M
AstraZeneca AZN:LN USD 2.12B 214M
Astrazeneca AZN:US USD 2.12B 214M
Biocryst Pharmaceuticals BCRX:US USD 3.61M 3.37M
Bristol Myers Squibb BMY:US USD 2.52B 167M
Eli Lilly And LLY:US USD 1.55B 31M
GlaxoSmithKline GSK:LN GBP 2.18B 209M
Johnson & Johnson JNJ:US USD 7.76B 29M
Karyopharm Therapeutics KPTI:US USD 980K 41K
MacroGenics MGNX:US USD 3.14M 741K
Merk MRK:US USD 3.36B 519M
Nektar Therapeutics NKTR:US USD 4.97M 143K
Novartis NVS:US USD 3.84B 180M
Novartis NOVN:VX USD 3.66B 92M
Pfizer PFE:US USD 9.82B 3.73B
Regeneron Pharmaceuticals REGN:US USD 317.8M 20.7M
Roche Holding ROG:VX 9.56B 717M
Takeda 4502:JP JPY 335.97B 30.53B
Ultragenyx Pharmaceutical RARE:US USD 8.63M 361K
YTE INCY:US USD 49.28M 4.05M